Distalmotion

Scores by criterion

Each criterion is defined on our methodology page.

Who uses Distalmotion and what it's for

DEXTER is cleared in the US for inguinal hernia repair, gallbladder removal, and hysterectomy, with further gynecology and ventral hernia filings in progress, and carries a CE mark in Europe for urology, gynecology, and general surgery.⁴

Its US sales focus on ambulatory surgery centers, including centers affiliated with HonorHealth, SCA, and Surgery Partners. Cypress Surgery Center in Wichita, Kansas, bought a DEXTER in March 2026 after finding the market leader's system too costly and too bulky for its rooms.^3,4

DEXTER

DEXTER pairs a sterile surgeon console, which lets the surgeon step to the bedside at any time, with patient-side arms on a mobile footprint. Distalmotion says it fits any size operating room without modifications and integrates with existing visualization and instruments.³

Chief executive Greg Roche told MD+DI the design targets the constraints of outpatient centers: room size, staffing, and sterile processing capacity.⁵

Funding and scale

Distalmotion raised $150 million in a Series G in 2025, with Johnson & Johnson's venture arm as a strategic investor, and Roche puts total funding at about $400 million. In 2026 it added a senior secured term loan of up to $70 million.^4,5

Roche said the company surpassed 3,000 cumulative procedures in the fourth quarter of 2025 and that the first quarter of 2026 was its best yet.⁴

Competitive landscape

Limits

Distalmotion publishes no system or per-procedure price, so the cost advantage it claims cannot be checked without a quote.³

US clearances cover a short list of procedures so far, which limits how many surgeons in a center can use the robot.⁴

Revenue is not disclosed. We estimate it at $25 million to $45 million a year, based on more than 3,000 procedures, a team of over 150 people, and a third-party estimate of about $45 million. This is an estimate, not a reported figure.^2,4

What customers say

Where it helps

Cynthia Meaux, market CEO of Cypress Surgery Center, said robotics was necessary for its program to grow but the economics had always been a barrier, and that with DEXTER the model finally makes sense.³

Steven Schwaitzberg, chairman of surgery at the University at Buffalo, is quoted by the company saying a robotics program in an outpatient facility without disrupting workflows is a game changer.¹

Where it falls short

We found no independent cost studies of DEXTER programs. Buyers should ask for instrument cost per case and service terms, since single-use instruments shift spending from sterilization to supplies.³

Leadership

• Greg Roche

  Chief executive officer

  Roche joined as CEO in December 2023 after running Avateramedical and leading robotics at Zimmer Biomet, where he launched the ROSA knee system.⁶

  Read full profile

Sources